NewEdge Advisors LLC Boosts Stake in Stryker Corporation $SYK

NewEdge Advisors LLC lifted its holdings in Stryker Corporation (NYSE:SYK) by 6.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 29,049 shares of the medical technology company’s stock after buying an additional 1,848 shares during the quarter. NewEdge Advisors LLC’s holdings in Stryker were worth $9,545,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Varma Mutual Pension Insurance Co increased its stake in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after buying an additional 5,100 shares during the period. QRG Capital Management Inc. grew its holdings in Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after acquiring an additional 4,186 shares in the last quarter. Swedbank AB increased its position in Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after purchasing an additional 7,934 shares during the period. Crossmark Global Holdings Inc. increased its position in Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after purchasing an additional 6,367 shares during the period. Finally, Cibc World Market Inc. raised its holdings in shares of Stryker by 11.9% in the 4th quarter. Cibc World Market Inc. now owns 157,822 shares of the medical technology company’s stock valued at $55,470,000 after purchasing an additional 16,790 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $338.85 on Monday. The business’s fifty day simple moving average is $320.11 and its 200-day simple moving average is $333.92. The company has a market cap of $129.97 billion, a PE ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter last year, the firm earned $3.13 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SYK shares. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research note on Friday, May 1st. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Needham & Company LLC reduced their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, BMO Capital Markets initiated coverage on Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.